These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18757184)

  • 21. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.
    Robbins JB; Schneerson R; Horwith G; Naso R; Fattom A
    Am Heart J; 2004 Apr; 147(4):593-8. PubMed ID: 15077073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. StaphVAX (Nabi).
    Jones T
    Curr Opin Investig Drugs; 2002 Jan; 3(1):48-50. PubMed ID: 12054071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges for a universal Staphylococcus aureus vaccine.
    Proctor RA
    Clin Infect Dis; 2012 Apr; 54(8):1179-86. PubMed ID: 22354924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a future for a Staphylococcus aureus vaccine?
    Proctor RA
    Vaccine; 2012 Apr; 30(19):2921-7. PubMed ID: 22115633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for active and passive immunization against Staphylococcus aureus.
    Shinefield HR; Black S
    Pediatr Infect Dis J; 2006 Feb; 25(2):167-8. PubMed ID: 16462297
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
    Shinefield HR
    Vaccine; 2006 Apr; 24 Suppl 2():S2-65-9. PubMed ID: 16823932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunity induced by Staphylococcus aureus surface protein A was protective against lethal challenge of Staphylococcus aureus in BALB/c mice.
    Yi SQ; Zhang XY; Yang YL; Yang Y; Liu SL; Fu L; Yu CM; Chen W
    Microbiol Immunol; 2012 Jun; 56(6):406-10. PubMed ID: 22420921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responses to a Staphylococcus aureus GapC/B chimera and its potential use as a component of a vaccine for S. aureus mastitis.
    Perez-Casal J; Prysliak T; Kerro-Dego O; Potter AA
    Vet Immunol Immunopathol; 2006 Jan; 109(1-2):85-97. PubMed ID: 16165220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.
    DeJonge M; Burchfield D; Bloom B; Duenas M; Walker W; Polak M; Jung E; Millard D; Schelonka R; Eyal F; Morris A; Kapik B; Roberson D; Kesler K; Patti J; Hetherington S
    J Pediatr; 2007 Sep; 151(3):260-5, 265.e1. PubMed ID: 17719934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide.
    Maira-Litran T; Kropec A; Goldmann D; Pier GB
    Vaccine; 2004 Feb; 22(7):872-9. PubMed ID: 15040940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.
    Nanra JS; Timofeyeva Y; Buitrago SM; Sellman BR; Dilts DA; Fink P; Nunez L; Hagen M; Matsuka YV; Mininni T; Zhu D; Pavliak V; Green BA; Jansen KU; Anderson AS
    Vaccine; 2009 May; 27(25-26):3276-80. PubMed ID: 19200819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing staphylococcal disease by disarming the immune responses to infection.
    Tarkowski A
    Arch Immunol Ther Exp (Warsz); 2000; 48(1):21-6. PubMed ID: 10722227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Staphylococcus aureus-specific IgA and agglutination potency in milk of cows by mucosal immunization.
    Tempelmans Plat-Sinnige MJ; Verkaik NJ; van Wamel WJ; de Groot N; Acton DS; van Belkum A
    Vaccine; 2009 Jun; 27(30):4001-9. PubMed ID: 19389449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.
    Zhang BZ; Hua YH; Yu B; Lau CC; Cai JP; Zheng SY; Yam WC; Kao RY; Sze KH; Zheng BJ; Yuen KY; Huang JD
    Infect Immun; 2015 Jan; 83(1):339-45. PubMed ID: 25368117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.
    Fattom A; Matalon A; Buerkert J; Taylor K; Damaso S; Boutriau D
    Hum Vaccin Immunother; 2015; 11(3):632-41. PubMed ID: 25483694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects".
    Jansen KU; Girgenti DQ; Scully IL; Anderson AS
    Vaccine; 2013 Jun; 31(25):2723-30. PubMed ID: 23624095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage.
    Clarke SR; Brummell KJ; Horsburgh MJ; McDowell PW; Mohamad SA; Stapleton MR; Acevedo J; Read RC; Day NP; Peacock SJ; Mond JJ; Kokai-Kun JF; Foster SJ
    J Infect Dis; 2006 Apr; 193(8):1098-108. PubMed ID: 16544250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staphylococci in colonization and disease: prospective targets for drugs and vaccines.
    Götz F
    Curr Opin Microbiol; 2004 Oct; 7(5):477-87. PubMed ID: 15451502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune proteomics of Staphylococcus aureus.
    Bröker BM; van Belkum A
    Proteomics; 2011 Aug; 11(15):3221-31. PubMed ID: 21710570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting surface protein SasX by active and passive vaccination to reduce Staphylococcus aureus colonization and infection.
    Liu Q; Du X; Hong X; Li T; Zheng B; He L; Wang Y; Otto M; Li M
    Infect Immun; 2015 May; 83(5):2168-74. PubMed ID: 25776748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.